Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jul 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020	Oct 31, 2019
Net Income	-12.36	-9.81	-13.6	-12.95	-10.02	-11.65
Depreciation & Amortization	0.04	0.05	0.04	0.06	0.09	0.47
Loss (Gain) From Sale of Assets	-	-	-	-0.01	0.15	-
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.42
Stock-Based Compensation	5.02	4.74	6.75	8.06	4.14	5.71
Other Operating Activities	-0.15	-0.12	-0.18	-0.17	-0.07	-0.17
Change in Accounts Receivable	-0.08	-0.22	-0.03	-	0.06	0.27
Change in Accounts Payable	0.21	-0.06	0.13	-0.1	-0.35	0
Change in Other Net Operating Assets	-1.07	-0.78	0.39	0.17	-0.17	0.2
Operating Cash Flow	-8.38	-6.21	-6.49	-4.94	-6.18	-4.74
Capital Expenditures	-	-	-	-	-0.02	-0.18
Sale of Property, Plant & Equipment	-	-	-	0.04	-	-
Investment in Securities	2.82	-5.6	-10.73	-3.96	-0.29	-0.35
Investing Cash Flow	2.82	-5.6	-10.73	-3.92	-0.31	-0.53
Issuance of Common Stock	3.73	0.37	0.45	31.57	9.41	5.69
Other Financing Activities	-0.14	-	-	-	-	0.01
Financing Cash Flow	3.59	0.37	0.45	31.57	9.41	5.7
Net Cash Flow	-1.97	-11.45	-16.77	22.71	2.93	0.44
Free Cash Flow	-8.38	-6.21	-6.49	-4.94	-6.19	-4.92
Free Cash Flow Margin	-	-2956.67%	-	-964.45%	-	-1966.75%
Free Cash Flow Per Share	-0.26	-0.20	-0.21	-0.17	-0.28	-0.25
Levered Free Cash Flow	-4.3	-3.02	-1.26	0.04	-2.64	-0.72
Unlevered Free Cash Flow	-4.3	-3.02	-1.26	0.04	-2.64	-0.72
Change in Net Working Capital	0.89	1.01	-0.52	-0.13	0.41	-0.45

Source: S&P Capital IQ. Standard template. Financial Sources.